AbbVie and OSE Immunotherapeutics announced a strategic partnership
AbbVie and OSE Immunotherapeutics, a clinical-stage immunotherapy company, today announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage. OSE-230 is a first-in-class monoclonal antibody designed to…